Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth Factor-BB in platelets

Aim: platelet-derived growth factor (pdgf)-bb plays a crucial role in atherosclerosis and vascular remodeling by promoting the migration and proliferation of vascular smooth muscle cells. the objective of this study was to clarify the pleiotropic effect of peroxisome proliferator-activated receptor α (pparα) activators on pdgf-bb expression in megakaryocytes and platelets. methods and results: the expression of pparα in a human erythroleukemia (hel) cells was clearly detected by reverse transcriptase-pcr and immunofluorescence microscopy. the expression level of pparα in hel cells was unchanged regardless of differentiation into megakaryocytic cells by treatment with phorbol 12-myristate 13 acetate (tpa). the tpa-induced expression of pdgf-b mrna and pdgf-bb protein levels in culture media was significantly decreased by treatment with pparα activators,wy14643 and fenofibric acid,in a dose-dependent manner. pdgf-bb expression induced by inflammatory cytokines,including interleukin-1β or interleukin-6,was also significantly suppressed by treatment with pparα activators. immunohistochemistry of human bone marrow showed the expression of pparα in both the nucleus and cytoplasm of megakaryocytes. in addition,pdgf-bb levels in platelets were significantly decreased from 1,800±870 to 1,470±840 pg/105 platelets (mean±sd,p<0.05) by treatment with 300 mg fenofibrate once daily for 4 weeks in 13 patients with dyslipidemia. conclusions: activation of pparα in megakaryocytes reduces pdgf-bb expression in platelets. pparα activators may exert vasculo-protective action through suppression of pdgf-bb production in a megakaryocyte/platelet pathway.